Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

Healthcare Drug Manufacturers - Specialty & Generic
"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

MERUS LABS INTERNATIONAL INC > TD
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by jammo71on Aug 17, 2016 7:45am
172 Views
Post# 25149100

RE:RE:TD

RE:RE:TD
lscfa wrote: You forgot the best part....F2017 estimate unchanged rev $122.1 million, adj. ebitda $64.7 million....


So right now the market is pricing MSL at just over 1x 2017 revenue and right around 2x 2017 earnings...

Either the market knows this is going in the crapper, or this is one of the biggest market inefficiencies I've seen in a while.

My bet's on the second. I sure hope I'm right. :D
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities